Status:

WITHDRAWN

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders

Lead Sponsor:

Merz Pharmaceuticals GmbH

Conditions:

Sleep-Disordered Breathing

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This proof-of-concept study is to assess the potential benefit of botulinum toxin for patients with sleep-related breathing disorders.

Detailed Description

Mono-center, double-blind, 1:1 randomized, placebo-controlled trial 18 treated patients, 9 patients per group. Patients will be randomly assigned to treatment with NT 201 or placebo in a ratio of 1:1...

Eligibility Criteria

Inclusion

  • Male and female outpatients of at least 18 years of age.
  • Patient who understand the nature of the study and provide written informed consent prior to protocol-specific procedures.
  • Patients suffering from sleep-related breathing disorders for at least 3 months prior to study start and seeking help for their snoring.
  • Non-REM RDI ≤ 25/h (according to Medicare Criteria) at baseline PSG.
  • AHI ≤ 10/h at baseline PSG.
  • Snoring Index ≥ 15 at baseline PSG.

Exclusion

  • Patients with known hypersensitivity to:
  • botulinum neurotoxin type;
  • any of the excipients (human albumin, sucrose).
  • Patients with upper respiratory tract pathology as assessed by an ear, nose, and throat \[ENT\] specialist.
  • Patients with generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome).
  • Patients with bleeding disorders of any type and/or receiving anticoagulant therapy.
  • Patients with a profound sleep disorder (pathological number and duration of episodes of hypopnea and apnea), upper airway resistance syndrome \[UARS\], or obstructive sleep apnea syndrome \[OSAS\].
  • Obese patients (BMI ≥ 30).
  • Presence of concomitant diseases:
  • severe or unstable cardiovascular (e.g. severe angina pectoris, post myocardial infarction and ventricular extra systoles), pulmonary, or endocrine disease; clinically relevant renal or hepatic disease or dysfunction; hematological disorder; any other clinically relevant medical condition that could increase the risk to the study participant;
  • malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer;
  • amyotrophic lateral sclerosis or other diseases which result in peripheral neuromuscular dysfunction;
  • risk of developing an angle closure glaucoma;
  • alcohol, drug, or medication abuse within the past year;
  • severe psychiatric or neurological disorders;
  • acute infections of the pharynx.
  • Patients likely to need concomitant medication as follows:
  • 4-aminochinolines;
  • aminoglycosides or spectinomycin, or other medical products interfering with neuromuscular transmission, e.g. tubocurarine-type muscle relaxants;
  • daily psychotropic medication;
  • regular intake or onset of hypnotics, e.g. benzodiazepines, chloralhydrate and combinations, barbiturates (except of mild phytotherapeutics, e.g. valerian, hop and combinations);
  • anti-snoring products during the course of the study such as foams, dental devices.
  • Pregnant or nursing women, or women of childbearing potential who are not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized/ hysterectomized.
  • Participation in a clinical study within the last 30 days prior to the start of the study.
  • Patients who are employees, relative or spouse of the investigator, of other staff of the investigational site or the sponsor or the CRO.
  • Any donation of germ cells, blood, organs, or bone marrow during the course of the study.
  • Patients who are expected to be non-compliant and/or not cooperative.
  • Patients who are not contractually capable.

Key Trial Info

Start Date :

March 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2010

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00773591

Start Date

March 1 2010

End Date

October 1 2010

Last Update

March 30 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders | DecenTrialz